Concepts (202)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia, Sickle Cell | 17 | 2023 | 339 | 2.820 |
Why?
|
| Hydroxyurea | 2 | 2020 | 204 | 0.790 |
Why?
|
| Erythrocyte Aging | 1 | 2011 | 14 | 0.400 |
Why?
|
| Trityl Compounds | 1 | 2011 | 3 | 0.400 |
Why?
|
| Antisickling Agents | 1 | 2011 | 12 | 0.400 |
Why?
|
| Hemolysis | 1 | 2011 | 127 | 0.380 |
Why?
|
| Cytapheresis | 1 | 2009 | 2 | 0.370 |
Why?
|
| Acetamides | 1 | 2011 | 113 | 0.360 |
Why?
|
| Vasodilator Agents | 2 | 2015 | 219 | 0.330 |
Why?
|
| Erythrocyte Transfusion | 1 | 2009 | 212 | 0.310 |
Why?
|
| Neoplasm Regression, Spontaneous | 1 | 2007 | 34 | 0.310 |
Why?
|
| Brain Stem Neoplasms | 1 | 2007 | 108 | 0.280 |
Why?
|
| Anemia | 2 | 2022 | 689 | 0.270 |
Why?
|
| Cerebral Infarction | 3 | 2014 | 59 | 0.270 |
Why?
|
| Glioma | 4 | 2007 | 1963 | 0.270 |
Why?
|
| Hemoglobin, Sickle | 4 | 2021 | 25 | 0.260 |
Why?
|
| Neonatal Screening | 2 | 2017 | 165 | 0.250 |
Why?
|
| Child | 23 | 2023 | 29154 | 0.250 |
Why?
|
| Magnesium Sulfate | 1 | 2014 | 39 | 0.240 |
Why?
|
| Child, Preschool | 16 | 2023 | 16273 | 0.240 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2014 | 160 | 0.220 |
Why?
|
| Blood Transfusion | 3 | 2021 | 583 | 0.210 |
Why?
|
| Interdisciplinary Communication | 1 | 2014 | 280 | 0.210 |
Why?
|
| Thrombocytosis | 1 | 2022 | 121 | 0.200 |
Why?
|
| Angola | 2 | 2018 | 5 | 0.200 |
Why?
|
| Recombinases | 1 | 2021 | 29 | 0.200 |
Why?
|
| Malaria | 1 | 2021 | 92 | 0.190 |
Why?
|
| Anemia, Iron-Deficiency | 1 | 2022 | 128 | 0.190 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2023 | 2594 | 0.180 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2022 | 362 | 0.180 |
Why?
|
| HIV Infections | 2 | 2022 | 2134 | 0.180 |
Why?
|
| Pain | 4 | 2017 | 1658 | 0.180 |
Why?
|
| Iron | 1 | 2022 | 376 | 0.170 |
Why?
|
| Neurofibromatosis 1 | 1 | 2001 | 144 | 0.170 |
Why?
|
| Malnutrition | 1 | 2022 | 218 | 0.170 |
Why?
|
| Pediatrics | 2 | 2018 | 1141 | 0.160 |
Why?
|
| Incidental Findings | 1 | 2010 | 272 | 0.160 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2011 | 7702 | 0.160 |
Why?
|
| Adolescent | 16 | 2023 | 31252 | 0.160 |
Why?
|
| Hemoglobins | 2 | 2022 | 477 | 0.160 |
Why?
|
| Paper | 1 | 2017 | 11 | 0.150 |
Why?
|
| Hematology | 1 | 2018 | 104 | 0.150 |
Why?
|
| Hematologic Diseases | 1 | 2018 | 242 | 0.150 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 846 | 0.150 |
Why?
|
| Blood Pressure | 2 | 2014 | 1467 | 0.150 |
Why?
|
| Maximum Tolerated Dose | 1 | 2020 | 1290 | 0.150 |
Why?
|
| Brain Diseases | 1 | 2010 | 403 | 0.140 |
Why?
|
| Analgesics, Opioid | 2 | 2023 | 1371 | 0.130 |
Why?
|
| Ikaros Transcription Factor | 1 | 2015 | 54 | 0.130 |
Why?
|
| Platelet Count | 2 | 2022 | 490 | 0.130 |
Why?
|
| Patient Care | 2 | 2018 | 149 | 0.130 |
Why?
|
| Magnesium | 1 | 2015 | 160 | 0.130 |
Why?
|
| Stroke | 1 | 2023 | 1144 | 0.120 |
Why?
|
| Humans | 31 | 2023 | 261506 | 0.120 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 672 | 0.120 |
Why?
|
| Body Height | 1 | 2014 | 231 | 0.120 |
Why?
|
| Infant | 8 | 2023 | 13310 | 0.110 |
Why?
|
| Length of Stay | 3 | 2015 | 1900 | 0.110 |
Why?
|
| Lamivudine | 2 | 2022 | 28 | 0.110 |
Why?
|
| Infant, Newborn | 6 | 2021 | 8223 | 0.110 |
Why?
|
| Male | 17 | 2022 | 123000 | 0.100 |
Why?
|
| beta-Thalassemia | 1 | 2011 | 17 | 0.100 |
Why?
|
| Global Health | 1 | 2017 | 657 | 0.100 |
Why?
|
| Intermediate-Conductance Calcium-Activated Potassium Channels | 1 | 2011 | 13 | 0.100 |
Why?
|
| Acute Chest Syndrome | 1 | 2011 | 9 | 0.100 |
Why?
|
| Female | 17 | 2022 | 141928 | 0.100 |
Why?
|
| Hematocrit | 1 | 2011 | 142 | 0.100 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 4320 | 0.090 |
Why?
|
| Quality Improvement | 2 | 2022 | 851 | 0.090 |
Why?
|
| Quality of Life | 3 | 2017 | 4532 | 0.090 |
Why?
|
| Body Weight | 1 | 2014 | 1293 | 0.090 |
Why?
|
| Double-Blind Method | 2 | 2015 | 2588 | 0.090 |
Why?
|
| Chest Pain | 1 | 2009 | 155 | 0.080 |
Why?
|
| Bone Marrow Transplantation | 1 | 2014 | 1581 | 0.080 |
Why?
|
| Multicenter Studies as Topic | 2 | 2023 | 543 | 0.080 |
Why?
|
| Young Adult | 6 | 2023 | 21445 | 0.080 |
Why?
|
| Tuberculosis | 1 | 2014 | 548 | 0.080 |
Why?
|
| Infusions, Intravenous | 2 | 2015 | 1382 | 0.070 |
Why?
|
| Hematologic Neoplasms | 1 | 2018 | 1870 | 0.070 |
Why?
|
| Retrospective Studies | 7 | 2023 | 37905 | 0.070 |
Why?
|
| Neurologic Examination | 1 | 2007 | 245 | 0.070 |
Why?
|
| Brain | 1 | 2010 | 4113 | 0.070 |
Why?
|
| Syndrome | 1 | 2009 | 1351 | 0.070 |
Why?
|
| Hospital Mortality | 2 | 2023 | 1274 | 0.070 |
Why?
|
| Respiratory Insufficiency | 1 | 2009 | 330 | 0.070 |
Why?
|
| Respiration, Artificial | 1 | 2009 | 577 | 0.070 |
Why?
|
| Internship and Residency | 1 | 2017 | 1375 | 0.070 |
Why?
|
| Emergency Service, Hospital | 2 | 2022 | 1148 | 0.070 |
Why?
|
| Follow-Up Studies | 4 | 2015 | 14889 | 0.060 |
Why?
|
| Risk Factors | 5 | 2022 | 17523 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 3472 | 0.060 |
Why?
|
| Hospitals, Special | 1 | 2014 | 24 | 0.060 |
Why?
|
| Narcotics | 1 | 2014 | 123 | 0.060 |
Why?
|
| Nevirapine | 1 | 2022 | 17 | 0.060 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2015 | 3552 | 0.060 |
Why?
|
| Academies and Institutes | 1 | 2023 | 95 | 0.050 |
Why?
|
| Glutathione Transferase | 1 | 2004 | 359 | 0.050 |
Why?
|
| Case-Control Studies | 2 | 2022 | 6100 | 0.050 |
Why?
|
| Prognosis | 3 | 2022 | 21713 | 0.050 |
Why?
|
| Hypotension | 1 | 2014 | 210 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2022 | 297 | 0.050 |
Why?
|
| Interprofessional Relations | 1 | 2014 | 213 | 0.050 |
Why?
|
| Cooperative Behavior | 1 | 2014 | 313 | 0.050 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 2796 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2004 | 614 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2023 | 447 | 0.050 |
Why?
|
| Neoplasms | 2 | 2014 | 15193 | 0.050 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2021 | 78 | 0.050 |
Why?
|
| Optic Nerve Glioma | 1 | 2001 | 31 | 0.050 |
Why?
|
| Informed Consent | 1 | 2014 | 419 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2011 | 2403 | 0.050 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 461 | 0.050 |
Why?
|
| Arginine | 1 | 2023 | 500 | 0.050 |
Why?
|
| Malawi | 1 | 2021 | 378 | 0.040 |
Why?
|
| Intensive Care Units, Pediatric | 1 | 2023 | 441 | 0.040 |
Why?
|
| Capacity Building | 1 | 2018 | 30 | 0.040 |
Why?
|
| Hospitals, Pediatric | 1 | 2014 | 773 | 0.040 |
Why?
|
| Brain Neoplasms | 2 | 2007 | 4849 | 0.040 |
Why?
|
| Africa South of the Sahara | 1 | 2018 | 101 | 0.040 |
Why?
|
| Reference Values | 1 | 2001 | 1099 | 0.040 |
Why?
|
| Confidence Intervals | 1 | 2010 | 756 | 0.040 |
Why?
|
| Point-of-Care Systems | 1 | 2021 | 196 | 0.040 |
Why?
|
| Death Certificates | 1 | 1998 | 17 | 0.040 |
Why?
|
| Probability | 1 | 2010 | 866 | 0.040 |
Why?
|
| Polymorphism, Genetic | 1 | 2004 | 1450 | 0.040 |
Why?
|
| United States | 3 | 2023 | 15433 | 0.040 |
Why?
|
| Isoelectric Focusing | 1 | 2017 | 49 | 0.040 |
Why?
|
| Sulfites | 1 | 2017 | 44 | 0.040 |
Why?
|
| Saponins | 1 | 2017 | 34 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2017 | 78 | 0.040 |
Why?
|
| Solubility | 1 | 2017 | 242 | 0.040 |
Why?
|
| Canada | 1 | 1998 | 429 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2015 | 2803 | 0.040 |
Why?
|
| Adult | 5 | 2011 | 77950 | 0.030 |
Why?
|
| Sex Factors | 1 | 2001 | 2139 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 390 | 0.030 |
Why?
|
| Alleles | 1 | 2021 | 2437 | 0.030 |
Why?
|
| Middle Aged | 5 | 2015 | 86204 | 0.030 |
Why?
|
| Texas | 2 | 2007 | 6311 | 0.030 |
Why?
|
| Cytokines | 1 | 2014 | 2809 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2014 | 130 | 0.030 |
Why?
|
| Infant Mortality | 1 | 2015 | 186 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 397 | 0.030 |
Why?
|
| Transfusion Reaction | 1 | 2014 | 102 | 0.030 |
Why?
|
| Ferritins | 1 | 2014 | 151 | 0.030 |
Why?
|
| Intelligence | 1 | 2014 | 126 | 0.030 |
Why?
|
| Health Status | 1 | 2017 | 590 | 0.030 |
Why?
|
| Anthropometry | 1 | 2014 | 269 | 0.030 |
Why?
|
| Karyotyping | 1 | 2015 | 1022 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2014 | 409 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 671 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2014 | 329 | 0.030 |
Why?
|
| Patient Selection | 1 | 2010 | 2055 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 4971 | 0.030 |
Why?
|
| Prevalence | 1 | 2010 | 3260 | 0.030 |
Why?
|
| Biomarkers | 1 | 2014 | 5047 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2015 | 875 | 0.030 |
Why?
|
| Aged | 3 | 2011 | 70117 | 0.030 |
Why?
|
| Allografts | 1 | 2014 | 650 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2011 | 32848 | 0.030 |
Why?
|
| Mass Screening | 1 | 2010 | 1509 | 0.030 |
Why?
|
| Asymptomatic Diseases | 1 | 2011 | 100 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2015 | 945 | 0.020 |
Why?
|
| Incidence | 1 | 2001 | 5673 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2011 | 495 | 0.020 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2010 | 6915 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2015 | 2232 | 0.020 |
Why?
|
| Aminoglycosides | 1 | 2010 | 220 | 0.020 |
Why?
|
| Daunorubicin | 1 | 2010 | 301 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2015 | 2508 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2010 | 568 | 0.020 |
Why?
|
| Etoposide | 1 | 2010 | 870 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 1998 | 6009 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2010 | 6869 | 0.020 |
Why?
|
| Family Health | 1 | 2007 | 325 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2007 | 1053 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2010 | 1656 | 0.020 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2004 | 69 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 4298 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2004 | 239 | 0.010 |
Why?
|
| SEER Program | 1 | 2007 | 1000 | 0.010 |
Why?
|
| Oligodendroglioma | 1 | 2004 | 106 | 0.010 |
Why?
|
| Cytarabine | 1 | 2010 | 1973 | 0.010 |
Why?
|
| Remission Induction | 1 | 2010 | 3569 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2010 | 3033 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2017 | 12873 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 4314 | 0.010 |
Why?
|
| Ependymoma | 1 | 2004 | 242 | 0.010 |
Why?
|
| Astrocytoma | 1 | 2004 | 321 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2010 | 3251 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2010 | 10001 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 3203 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2010 | 4367 | 0.010 |
Why?
|
| Logistic Models | 1 | 2004 | 3441 | 0.010 |
Why?
|
| Survival Rate | 1 | 2010 | 12221 | 0.010 |
Why?
|
| Genotype | 1 | 2004 | 4109 | 0.010 |
Why?
|
| Mutation | 1 | 2015 | 15179 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2004 | 4988 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2007 | 5539 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2004 | 5112 | 0.010 |
Why?
|
| Time Factors | 1 | 2004 | 12926 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2010 | 15862 | 0.000 |
Why?
|